Skip to main content
SpringerLink
Log in

Linzolid: first of a new drug class for Gram-positive infections

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Diekema D, Jones R. Oxazolidinones: a review. Drugs 2000; 59(1): 7–16

    Article  PubMed  CAS  Google Scholar 

  2. Clemett D, Markham A. Linezolid. Drugs 2000; 59(4): 815–27

    Article  PubMed  CAS  Google Scholar 

  3. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 2001; (61) 4: 525–551

    Article  Google Scholar 

  4. Pharmacia and Upjohn Company. Kalamazoo, USA. Linezolid prescribing information. Available from: URL: http://www.zyvox.com/fullprescribe.htm [Accessed 2001 Apr 12]

  5. Wise R. Linezolid: a viewpoint by Richard Wise. Drugs 2000; 59(4): 828

    Article  Google Scholar 

  6. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839–45

    PubMed  CAS  Google Scholar 

  7. Schaadt RD, Batts DH, Daley-Yates PT, et al. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid. Diagn Microbiol Infect Dis 1997; 28: 201–4

    Article  PubMed  CAS  Google Scholar 

  8. Cammarata SK, Hafkin B, Demke DM, et al. Efficacy of linezolid in skin and soft tissue infections [abstract]. Clin Microbiol Infect 1999; 5 Suppl. 3: 133

    Google Scholar 

  9. Cammarata SK, Hafkin B, Todd WM, et al. Efficacy of linezolid in community-acquired S. pneumoniae pneumonia [abstract]. Am J Respir Crit Care Med 1999; 159 Suppl. Pt 2 (3): A844

    Google Scholar 

  10. Anon. First resistance to linezolid reported. Scrip Mag 1999 Oct 6; 2478: 23

  11. Lobeck F, Anderson DC, Bruss JB, et al. Linezolid for the treatment of pneumonia in hospitalized children: an open-label, single-arm, multicenter study [abstract]. 9th International Congress on Infectious Diseases; Apr 10–13: Buenos Aires, 117

  12. Birmingham MC, Zimmer GS, Hafkin B, et al. Outcomes with linezolid from an ongoing compassionate use (CU) trial of patients (pts) with significant, resistant Gram-positive infections [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Nov 18–24; Buffalo, NY: 724

    Google Scholar 

  13. Birmingham MC, Zimmer GS, Flavin SM, et al. Results of treating bacteraemic patients with linezolid in a compassionate use trial for resistant, gram-positive infections [abstract]. Proceedings of the 37th Annual Meeting of the Infectious Diseases Society of America; 1999 Nov 18–21; Philadelphia, PA: 129

    Google Scholar 

  14. Duvall SE, Sseas C, Bruss JB, et al. Comparison of oral linezolid to oral Clarithromycin in the treatment of uncomplicated skin infections: results from a multinational phase III trial [abstract]. 9th International Congress on Infectious Diseases; 2000 Apr 10–13: Buenos Aires, 181

    Google Scholar 

  15. Cammarata SK, Schueman LK, Timm JA, et al. Oral linezolid in the treatment of community-acquired pneumonia: a phase III trial [poster no. E-73]. American Thoracic Society; 2000 May 5: Toronto

    Google Scholar 

  16. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44(12): 3408–13

    Article  PubMed  CAS  Google Scholar 

  17. Cammarata SK, San Pedro GS, Timm JA, et al. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized patients with community-acquired pneumonia [poster no. 237]. American Thoracic Society 2000 May 5, Toronto

    Google Scholar 

  18. Cammarata SK, Hempsall KA, Timm JA, et al. Linezolid is superior to Cephalosporins in treatment of patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia [abstract]. Am J Resp Crit Care Med 2000; 161 Pt 2 suppl. A654

    Google Scholar 

  19. Leach TS, Kaja RW, Eckert SM, et al. Linezolid versus vancomycin for the treatment of MRS A infections: results of a randomized phase III trial [abstract]. 9th International Congress on Infectious Diseases; 2000; Apr 10–13: Buenos Aires, 224

    Google Scholar 

  20. Rubinstein E, Cammarata SK, Oliphant TH, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2000; 32: 402–12

    Article  Google Scholar 

  21. Hartman CS, Leach TS, Kaja RW, et al. Linezolid in the treatment of vancomycin-resistant enterococcus: a dose comparative, multicenter phase III trial [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20: Toronto, 488

    Google Scholar 

  22. Fines M, Leclercq R. Influence of mechanisms of resistance to antiobiotics that bind to the 50S ribosomal subunit on the activity of linezolid against gram-positive organisms. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, CA: C183

    Google Scholar 

  23. Zurenko GE, Todd WM, Hafkin B, et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with Linezolid [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 24–2; San Francisco, CA: 118

    Google Scholar 

  24. Wilks NE, McConnell-Martin MA, Oliphant TH. Safety and tolerance of linezolid in phase II trials [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 24–27; San Francisco, CA: 40

    Google Scholar 

  25. Noskin GA. Linezolid: a viewpoint by Gary A. Noskin. Drugs 2000; 59(4): 828

    Article  Google Scholar 

  26. Rittenhouse BE, Li Z, Willke RJ, et al. Re-examining hospital length of stay (LOS) reduction potential in a randomized, multi-center clinical trial of methicillin-resistant Staphylococcal species (MRSS): linezolid vs. vancomycin [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20: Toronto, 510

    Google Scholar 

  27. Li ZJ, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001; 21(3): 263–274

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Linzolid: first of a new drug class for Gram-positive infections. Drugs Ther. Perspect 17, 1–6 (2001). https://doi.org/10.2165/00042310-200117090-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117090-00001

Keywords

Search

Navigation